This article summarises a selection of scientific highlights in the field of interstitial lung
diseases (ILDs) presented at the International Congress of the European Respiratory …

Background and objective Patients with interstitial lung disease (ILD) are often prescribed
disease‐targeted and symptomatic therapies, both of which can cause significant treatment …

Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by a
spectrum of inflammatory and fibrotic changes affecting alveolar walls and airspaces¹-7 …

Fibrosing interstitial lung disease (ILD) is one of the most important causes of morbidity and
mortality in patients with connective tissue diseases (CTDs), which include systemic …

© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2023; 15 (4): 1555-1558|
https://dx. doi. org/10.21037/jtd-23-316 study by Kaseda et al. explores predictors of adverse …

Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function …

The 10th anniversary of The Lancet Respiratory Medicine is an appropriate time to
acknowledge advances in the management of interstitial lung disease (ILD) and to …

The management of interstitial lung disease (ILD) may benefit from a conceptual shift.
Increased understanding of this complex and heterogeneous group of disorders over the …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–
induced coronavirus disease (COVID-19) dominated the year 2020. Initial reports of the long …

Idiopathic pulmonary fibrosis (IPF), the most common of the idiopathic interstitial
pneumonias, is a devastating condition that carries a prognosis worse than that of many …